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ABSTRACT
Adjuvant chemotherapy for early breast cancer im-
proves disease-free and overall survival in pre- and 
postmenopausal women. The importance of main-
taining relative dose intensity (rdi) is well-known; 
however, little information is available from routine 
clinical practice regarding how well dose intensity 
is maintained with modern chemotherapy regimens.
In a retrospective review of patients undergoing 
chemotherapy for early breast cancer at a single in-
stitution in Canada from January 2006 to November 
2007, a total of 263 patients received one of the fol-
lowing regimens:
●    ac-t [doxorubicin (Adriamycin: Pharmacia, 
Kalamazoo, MI, U.S.A.)–cyclophosphamide, pa-
clitaxel (Taxol: Bristol–Myers Squibb, Princeton, 
NJ, U.S.A.)]
●    fec-100 (5-fluorouracil–epirubicin–cyclophosph-
amide)
●    fec-d (5-fluorouracil–epirubicin–cyclophosph-
amide, docetaxel)
Overall, only 14.4% of patients had a rdi less than 
85%. Dose delay or reduction (or both) occurred in 
46%, 37%, and 20% of patients receiving fec-100, 
ac-t, and fec-d respectively. Optimal rdi was deliv-
ered to 96%, 95%, and 70.7% of patients for ac-t, 
fec-d and fec-100 regimens respectively. Patients 
over 65 years of age accounted for 14% of the total 
cohort and were more likely to receive a suboptimal 
rdi than were patients younger than 65 years of age 
(35% vs. 6.6%).
Optimal chemotherapy  rdi (>85%) for early 
breast cancer can be achieved at an academic cancer 
centre. This goal is less often accomplished in elderly 
patients, and thus a proactive approach is required for 
managing toxicity in that population.
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1.  INTRODUCTION
Breast cancer is the most common form of cancer 
affecting women in Canada, with more than 22,200 
new cases being diagnosed and 5300 deaths occurring 
annually 1. Early breast cancer (ebc) is considered 
to be a potentially curable disease. Surgery remains 
the definitive treatment for ebc. Adjuvant systemic 
therapy, such as chemotherapy or hormonal treat-
ment, is administered depending upon stage, grade, 
and other tumour characteristics.
In premenopausal women, adjuvant chemotherapy 
reduces the risk of disease relapse by 37% and of death 
by 30%. For women aged 50 to 69 years, the risk reduc-
tions are 19% (relapse) and 12% (death). The conferred 
absolute gain in survival appears to depend on the 
magnitude of risk of recurrence at presentation 2.
To achieve the full benefit of chemotherapy in 
potentially curable ebc, maintaining dose intensity 
is very important. In chemotherapy regimens, there 
is good evidence for a threshold of delivered relative 
dose intensity (rdi), below which the clinical benefits 
may become compromised 3. Many clinicians and 
quality assurance programs have adopted the rdi cri-
terion of Bonadonna et al. in adjuvant chemotherapy 
for ebc 3.
The benefit of maintaining dose intensity is not 
limited to breast cancer. Trials in non-Hodgkin lym-
phoma (nhl) have demonstrated similar improvements 
in disease-free survival and overall survival if dose 
intensity is maintained above a certain level 4,5.
Despite the fact that maintaining rdi is important 
to achieve improved outcome, many patients in adju-
vant settings are treated with a lower dose intensity 
of chemotherapy. Lyman et al. reported a survey of 
more than 20,000 women with ebc, which showed 
that 55% of women received less than 85% of the 
rdi 6. A similar trend of dose reduction was reported 
in more than 4500 patients with aggressive nhl. In 
that survey, dose reductions of 15% or more occurred 
in 40% of patients, and treatment delays up to 7 days 
occurred in 24% of patients 7. Most of the patients 
in the ebc study reported by Lyman et al. 6 received 
cmf [cyclophosphamide, methotrexate, 5-fluorouracil 
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(5fu)], caf (cyclophosphamide, doxorubicin, 5fu), or 
ac [doxorubicin (Adriamycin: Pharmacia, Kalama-
zoo, MI, U.S.A.), cyclophosphamide] chemotherapy 
regimens, which are now less frequently used for 
adjuvant treatment of ebc.
Considering the importance of maintaining dose 
intensity in the adjuvant setting 8, we conducted a 
retrospective analysis in patients with ebc treated at a 
Canadian centre with adjuvant chemotherapy consist-
ing of fec-100 (5fu–epirubicin–cyclophosphamide), 
ac-t [doxorubicin (Adriamycin)–cyclophosphamide, 
paclitaxel (Taxol: Bristol–Myers Squibb, Princeton, 
NJ, U.S.A.)], or fec-d (5fu–epirubicin–cyclophosph-
amide, docetaxel). We also analyzed the incidence of 
febrile neutropenia in this patient population. Here, 
we report our experience with delivered rdi in these 
patients receiving the most recent generation of ad-
juvant chemotherapy regimens.
2.  PATIENTS AND METHODS
After obtaining local ethics board permission to con-
duct the study, data were collected retrospectively in 
a chart review of 275 ebc patients treated from Janu-
ary 2006 to November 2007 at the London Regional 
Cancer Program, London, Ontario, Canada. Chart 
data was extracted only for those patients (Table i) 
who were treated with one of the following regimens: 
ac-t (4 cycles of doxorubicin–cyclophosphamide, 
followed by 4 cycles of paclitaxel, all given once 
every 3 weeks), fec-100 (6 cycles of 5fu–epirubicin–
cyclophosphamide, once every 3 weeks), or fec-d (3 
cycles of fec-100 followed by 3 cycles of docetaxel, 
all given once every 3 weeks).
Data collection included pretreatment de-
mographics and clinical characteristics, particu-
larly age at diagnosis, chemotherapy regimen, and 
planned dose and schedule. All episodes of febrile 
neutropenia were also recorded for each patient 
across all cycles.
The primary objective was to calculate the deliv-
ered rdi, defined as the proportion actually received 
of the reference standard dose intensity for each 
regimen. The numbers of patients receiving less or 
more than 85% of the rdi were recorded separately. 
Incidences of chemotherapy dose delays of more than 
7 days or dose reductions of more than 15% were 
recorded for all chemotherapy cycles.
Summative dose intensity (sdi) is a concept ap-
plied to clinical trials in which the relationships of dose 
intensity with effects are studied. The sdi is defined as 
the sum of the contributions of individual drug dose 
intensities in a combination drug regimen, and here, 
it is calculated based on the work of Hryniuk et al. 12 
Hryniuk et al. showed a positive relationship between 
higher dose intensities and better outcomes in patients 
with ebc, and those data have served as the ground-
work for many trials starting in the late 1980s.
The sdi of each regimen is calculated in four steps:
●    First, a unit dose intensity (udi—the dose of 
the drug required to produce 30% complete 
responses, plus partial responses, when used as 
a first-line single-agent chemotherapy in meta-
static breast cancer) is calculated for each drug 
in the combination regimen. The udis for 5fu, 
epirubicin, and cyclophosphamide are 650, 25, 
and 700 respectively.
●    In the second step, the dose intensity of each drug 
in a combination is expressed as a fraction of it 
own udi. The individual dose in milligrams per 
square metre body surface area is converted to a 
per-week fraction. For example, in the fec-100 
regimen, cyclophosphamide and 5fu at 500 mg/
m2 every 3 weeks becomes 167/week, and epi-
rubicin at 100 mg/m2 every 3 weeks becomes 
33.33/week.
●    In the third step, the calculated weekly standard 
dose from step 2 is divided by the udi from step 1 
to yield the sdi of the individual drug (Table ii 
shows the sdis of the studied regimens). For ex-
ample, for 5fu, 167/650 produces an sdi of 0.26. 
The corresponding results for epirubicin and cy-
clophosphamide are 1.33 and 0.23 respectively.
●    In the last step, the sdis of the regimen are summed. 
For fec-100, the final sdi is therefore 1.82.
table i  Characteristics of the treatment received by the study 
patients
Treatment Patients
characteristic Overall Age<65 Age≥65
( N = 263) (86%) (14%)
ac/t n=100 93% 7%
fec/d n=98 91.8% 8.2%
fec 100 n=65 66.1% 33.9%
rdi > 85% 89.9% 93.3% 64.8%
Dose delay > 7 days 14.4% 15% 10.8%
Dose reduction 22% 16.8% 54%
rdi = relative dose intensity.
table ii  Chemotherapy regimens: reference standard dose, sched-
ule, and summative dose intensity (sdi)
aC/t 9 feC/d 10 feC 100 11
(n=100) (n=100) (n=75)
Cycle length (days) 21 21 21
Doxorubicin [a (mg/m2)] 60
Cyclophosphamide  
[c (mg/m2)]
600 500 500
Paclitaxel [t (mg/m2)] 175
Fluorouracil [f (mg/m2)] 500 500
Docetaxel [d (mg/m2)] 100
Cycles given (n) ac×4, t×4 fec×3, 
d×4
fec×6
sdi 3 3.8 1.810
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If a patient experiences a dose reduction of 25% 
in 6 cycles of fec-100, the drop for the total dose 
of 5fu would be to 2250 mg/m2 from 3000 mg/m2 
over 18 weeks. The corresponding dose intensity 
would be calculated at 125/week to yield a final sdi 
of 0.178. In this case scenario, the sdis for epirubicin 
and cyclophosphamide would be 1 and 0.192, thereby 
delivering a 1.37 sdi for the regimen. Thus, with this 
reduction in the dose, the delivered rdi is 1.37/1.82 
(about 75%). In randomized trials in which dose in-
tensity is tested, response rates and survival were lin-
early associated with the sdi in each treatment arm 6.
3.  RESULTS
Of the 263 evaluable patients, 98 received fec-d; 
100, ac-t; and 65, fec-100. Overall, 14.4% of the 
patients experienced a dose delay of 1 week or more, 
and 22% experienced a dose reduction of any degree 
(Table i). About 33% of all patients experienced either 
dose reduction or dose delay, but overall only 14.4% 
received less than 85% of the rdi.
Dose delays were noted in 25%, 13%, and 0% of 
patients receiving ac-t, fec-d, and fec-100 respec-
tively, and dose reductions were noted in 18%, 10.2%, 
and 46% respectively. Dose delay or reduction was 
found in 46% of patients treated with fec-100, in 37% 
treated with ac-t, and in 20% treated with fec-d. The 
delivered rdi was above 85% in 96%, 95%, and 70.7% 
of the ac-t, fec-d, and fec-100 regimens (Figure 1).
In our study population, 14% patients were 65 
years of age or older. Of the patients treated with 
fec-100, 33.8% were over 65 years of age as com-
pared with 8.2% of patients treated with fec-d and 
7% treated with ac-t.
The delivered rdi was less than 85% in approxi-
mately 35% of patients 65 years of age or older, as 
compared with 6.6% of patients younger than 65 
years of age. Overall, for the 65-or-older age group, 
the incidence of febrile neutropenia was 27% as com-
pared with 16.3% for patients under 65 years of age 
(Figure 2). The overall incidence of febrile neutropenia 
was 17.8%, being observed at rates of 26.1%, 23.4%, 
and 7% in the fec-100, fec-d, and ac-t regimens re-
spectively (Figure 3). Most of the febrile neutropenia 
episodes in patients treated with the fec-d regimen (19 
of 23) coincided with the first cycle of docetaxel.
4.  DISCUSSION AND CONCLUSIONS
4.1  Delivered RDI
We analyzed data for patients receiving three fre-
quently used adjuvant chemotherapy regimens for 
ebc, utilizing appropriate methods to calculate the 
delivered rdis. Considering the importance of rdi, 
we hope that our data will help other physicians to 
calculate rdi for their patients. Data from previously 
published trials demonstrate that ebc patients treated 
figure 3  Rate of febrile neutropenia (feb/neut) by chemo-
therapy regimen.  feC100 = 5-fluorouracil (5fu)–epirubicin–
cyclophosphamide; feC-d = 5fu–epirubicin–cyclophosphamide, 
docetaxel; aC-t = doxorubicin (Adriamycin: Pharmacia, Kalamazoo, 
MI, U.S.A.)–cyclophosphamide, paclitaxel (Taxol: Bristol–Myers 
Squibb, Princeton, NJ, U.S.A.).
figure 1  Dose delay, dose reduction, and relative dose intensity 
(rdi) for the chemotherapy regimens. feC-d = 5-fluorouracil (5fu)–
epirubicin–cyclophosphamide, docetaxel;  aCt-t = doxorubicin 
(Adriamycin: Pharmacia, Kalamazoo, MI, U.S.A.)–cyclophosph-
amide, paclitaxel (Taxol: Bristol–Myers Squibb, Princeton, NJ, 
U.S.A.); feC-100 = 5fu, epirubicin, cyclophosphamide.
figure 2  Febrile neutropenia (Feb/Neu) and relative dose intensity 
(rdi) in the study population, by patient age.11
Current OnCOlOgy—VOlume 16, number 6
RAZA et al.
with adjuvant chemotherapy are at considerable 
risk of reduced delivered rdi 6,7. However, our data 
analysis has been encouraging: It showed that the rdi 
received by most of our patients exceeded 85%.
This result is likely attributable to multiple fac-
tors. Our medical oncology group adheres to breast 
cancer treatment guidelines when evaluating systemic 
therapy plans for patients with ebc. There is general 
awareness among medical oncologists about the im-
portance of the relationship between dose intensity 
and outcome in  ebc. Several previous trials have 
provided data showing improved outcomes with 
maintenance of rdi during adjuvant chemotherapy for 
ebc 13,14. A 20% dose reduction may compromise cure 
by 50%, and patients receiving less than 65% dose 
intensity are expected to have a survival similar to that 
of an untreated control group 15. Randomized clinical 
trials have shown that granulocyte colony–stimulating 
factor (g-csf) can reduce the risk of complications 
associated with chemotherapy and also facilitate the 
delivery of full-dose rdi 16. The accessibility and more 
frequent use of growth factors could be another reason 
behind our results. For the patients reviewed here, the 
use of g-csf was limited to patients with documented 
febrile neutropenia, and none of the patients was 
treated with g-csf as primary prophylaxis. Earlier 
surveys showing a lower delivered rdi in ebc patients 
focussed on community medical oncology practices. 
Our centre, being an academic cancer centre, may 
certainly have had a different approach to managing 
patients from the perspective both of the physicians 
and the nursing staff and of resources, accounting for 
a different outcome.
4.2  Occurrence and Management of Febrile  
Neutropenia
Generally, elderly women are considered to be more 
prone to chemotherapy-related side effects, includ-
ing febrile neutropenia, which may have translated 
to a reduced rdi for this group of women within the 
study sample. Among fec-100 treated patients, the 
incidence of febrile neutropenia was high, and more 
frequently, these patients received a lesser rdi. How-
ever, a relatively smaller number of patients were 
treated with the fec-100 regimen. These findings cor-
relate well with the fact that 34% of patients treated 
with the fec-100 regimen were more than 65 years 
of age (compared with 16% and 7% of the patients 
treated with fec-d and ac-t). In addition, the fec-100 
recipients appeared to have more comorbid illnesses 
than did patients receiving other adjuvant combina-
tion chemotherapy.
The fec-d regimen is an effective, relatively new, 
but quite frequently-used combination for ebc in the 
adjuvant setting. The reported incidence of febrile neu-
tropenia with fec-d in the pacs 01 trial (Sequential Ad-
juvant Epirubicin-Based and Docetaxel Chemotherapy 
for Node-Positive Breast Cancer Patients) was around 
11% 10; however, our experience shows a higher risk 
of febrile neutropenia (23%). Interestingly, most of 
the febrile neutropenia incidences were reported with 
the first dose of docetaxel (cycle 4), consistent with 
the observations in the pacs 01 trial. Other Canadian 
cancer centres have experienced similar trends in the 
incidence of febrile neutropenia with the fec-d regi-
men (Ottawa and Sudbury cancer centres. Personal 
communication). With such a high rate of febrile neu-
tropenia, we should consider giving g-csf as primary 
prophylaxis with fec-d, possibly starting from cycle 1, 
but at least for the last 3 cycles.
4.3  Study Limitations
The present study is limited by its retrospective design 
and small sample size. However, we feel that it still 
represents a reasonable cross-sectional view of the 
management of ebc in a Canadian academic cancer 
centre. The three regimens analyzed were in use at 
different times. The ac-t combination was used be-
tween 2001 and 2004, and many patients included in 
the review were part of the National Cancer Institute 
of Canada Clinical Trials Group ma.21 trial. Thus 
a potential selection bias related to those patients 
may be present. The fec-100 regimen came into use 
around 2005 and was initially believed to be carrying 
relatively fewer side effects. That belief may have 
contributed more elderly patients to that group. The 
fec-d regimen is the newest and has been particularly 
used in lymph-node-positive patients. Thus, almost a 
decade has gone into the selection of these patients, 
and changes in physician practices, guidelines, and 
other factors may potentially have injected some 
biases into the outcomes reported.
4.4  Summary
We hope that these data can help physicians to become 
more aware of the importance of maintaining optimal 
dose intensities for adjuvant chemotherapy treatment 
in ebc. We believe that improvements in the overall 
management of such patients will lead to doses in the 
frequently used chemotherapy regimens being main-
tained close to the optimal rdi. Because elderly patients 
derive benefits from the use of adjuvant chemotherapy 
similar to those seen in their younger peers, particular 
attention should be paid to the need to improve deliv-
ered rdi in the elderly patient population. A proactive 
role to address chemotherapy-related side effects and 
the use of g-csf may help to achieve that goal.
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